Rates of type 2 diabetes are higher in people with one of various common psychiatric disorders

A new study published in Diabetologia (the journal of the European Association for the Study of Diabetes (EASD)) finds that the prevalence of type 2 diabetes (T2D) is elevated in people with a psychiatric disorder compared with the general population. The research was conducted by Nanna Lindekilde, Department of Psychology, University of Southern Denmark, Odense, Denmark, and colleagues.
Psychiatric disorders are common, impair the quality of life and are associated with increased mortality rates. This excess mortality is caused in part by more frequent suicides and accidents, but also by an elevated risk of developing physical conditions known to be linked to mental health problems such as cardiovascular and respiratory diseases. Diabetes is an increasingly common disease throughout the world and estimates suggest that 6% to 9% of the global general population are currently affected. Rates have been rising since 1990 onwards in a trend that is expected to continue for the next 20 years.
Previous research has found that the prevalence of T2D is higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population. Despite this, no systematic overview of this research is currently available to examine the possible links between prevalence of T2D and psychiatric disorders in general.
The authors conducted an in-depth search of four electronic databases of scientific papers and found 32 systematic reviews based on 245 unique primary studies. There were 11 categories of disorders: schizophrenia, bipolar disorder, depression, substance use disorder, anxiety disorder, eating disorder, intellectual disability, psychosis, sleep disorder, dementia, and a ‘mixed’ group that comprised different types of psychiatric disorders.
The study found that people with a sleep disorder had the highest rates of T2D with 40% of subjects having the disease while its prevalence among individuals with other psychiatric disorders was 21% (binge eating disorder), 16% (substance use disorder), 14% (anxiety disorders), 11% (bipolar disorder), and 11% (psychosis). Prevalence of T2D was lowest among people with an intellectual disability with 8% of individuals having the disease. In each case these rates are as high or higher than the 6-9% level of T2D found in the general population.
The researchers explain that sleep disorders constitute a subgroup of psychiatric disorders and have high comorbidity with several other diseases. In the review, most of the primary studies were conducted among people with additional diseases such as chronic kidney disease. The authors say: “It is likely that this physical comorbidity contributes to the high T2D prevalence estimates in people with a sleep disorder. The link between T2D and sleep disorders is likely to be bidirectional with the sleep disorder raising the risk of developing diabetes, while diabetes, especially in combination with poor metabolic control, increasing the risk of developing sleep problems.”
While the authors found that people with any of the investigated psychiatric disorders are more likely to have T2D than the general population, they caution: “More refined comparisons should be made between prevalence estimates in the future to better account for differences in populations groups, study settings and the broad range of years as well as methods used to ascertain T2D.” For example, a study conducted in the United States might be expected to show higher rates of diabetes than the global average (including among people with a psychiatric disorder) simply due to differences in demographics and obesity rates between the US population and that of the world as a whole.
They conclude: “Increased prevalence of type 2 diabetes among individuals with a psychiatric disorder suggests that these conditions have a shared vulnerability to the development of the condition relative to the population at large. Better understanding of the observed differences in disease risk and the reasons behind them are still needed. Reliable information about prevalence and a better understanding of biological and behavioural factors driving increased prevalence of type 2 diabetes in people with a psychiatric disorder will be crucial to developing cost-effective strategies for the management of patients in this situation.”
Story Source:
Materials provided by Diabetologia. Note: Content may be edited for style and length.

Read more →

Letter From Catherine the Great Shows Her Support for Inoculations

In a letter from 1787 to be sold at auction this week, the Russian empress called for widespread access to a precursor of the smallpox vaccine.As smallpox outbreaks ravaged communities in the 18th century, one of the first people in Russia to embrace a precursor to vaccines was Catherine the Great, the empress famed for promoting the latest knowledge in the arts and sciences from her throne.Catherine’s support for an early form of inoculation is captured in a letter to be sold at auction in London on Wednesday. In it, she instructs a governor-general to ensure that a smallpox prevention method called variolation was readily available in his province.According to a translation of the letter provided by the auction house, Catherine, like many world leaders today, sought widespread protection against an infectious disease that was devastating her empire. “Such inoculation should be common everywhere,” she wrote, “and it is now all the more convenient, since there are doctors or medical attendants in nearly all districts, and it does not call for huge expenditure.”MacDougall’s, an auction house in London that specializes in Russian art, is auctioning the letter along with a portrait of Catherine by Dmitry Levitsky. In the portrait, the empress wears a small crown and an ermine-lined cloak.The items together are worth an estimated $1 million to $1.6 million, according to the auction house.The auction house listing does not identify the current owner of the objects, but it says they are from a private collection in Russia. The painting was previously exhibited in museums in St. Petersburg and Moscow, it says.A director of the auction house, Catherine MacDougall, said the initial announcement about the auction led to more than 100 interview requests from news organizations in Russia, where there is great interest in Catherine’s inoculation efforts.Variolation “should be common everywhere,” Catherine wrote, “and it is now all the more convenient, since there are doctors or medical attendants in nearly all districts.”MacDougall Auctions The letter is dated April 20, 1787, and addressed to a Russian army officer, Piotr Aleksandrovich Rumiantsev, who was known as Count Zadunaysky. Catherine wrote in the letter that one of Rumiantsev’s most important duties “should be the introduction of inoculation against smallpox, which, as we know, causes great harm, especially among the ordinary people.”Catherine and her son Pavel Petrovich were inoculated nearly two decades earlier, in 1768.At the time, people were inoculated using variolation, the practice of exposing people to material from an infected pustule of a patient with smallpox. The process was used for hundreds of years in India and China before being adopted in Europe. Enslaved people from Africa introduced the treatment in the United States. It is similar to, but distinct from, vaccination, which uses a less harmful version of a virus.Many people were wary of the practice, which sometimes led to deaths or outbreaks of a mild form of smallpox.These concerns prompted Catherine to show her support for it.Lynne Hartnett, an associate professor of history at Villanova University, said Catherine was terrified of smallpox, which had infected her husband and killed the fiancée of one of her closest advisers.She invited an English physician, Thomas Dimsdale, to St. Petersburg to inoculate her, her son and members of her court. “She was doing it as a way to show the Russian people that it was safe and it could keep this disease at bay,” Professor Hartnett said.Catherine provided Dimsdale with a carriage and protection in case she died and he needed an urgent route out of Russia. Instead, she recovered from the inoculation and a holiday was declared to celebrate the event.Afterward, Catherine wrote to her ambassador in Britain, Count Ivan Grigorievuch Chernyshev: “Starting with me and my son, who is also recovering, there is no noble house in which there are not several vaccinated persons, and many regret that they had smallpox naturally and so cannot be fashionable.”

Read more →

Telehealth-delivered diet and exercise program eased knee pain and triggered weight loss

New research investigating the benefits of telehealth-delivered exercise and diet programs has found 80 per cent of participants experienced improvement in pain and an average of 10 per cent in loss of body weight, with one man shedding 39 kilograms.
More than 400 individuals with knee osteoarthritis participated in the Better Knee, Better Me trial, developed by the University of Melbourne in partnership with Medibank and Austin Health.
Published in the Annals of Internal Medicine today, the study shows researchers evaluated two six-month telehealth-delivered exercise programs, one with and one without a weight-loss dietary program, compared with an information-only control group.
During the trial, participants in the intervention groups were provided support from physiotherapists and dietitians via Zoom and a suite of resources. Those in the exercise plus diet group also received meal replacements so they could undertake a ketogenic low energy diet.
Compared to the group that only received information, both intervention programs resulted in benefits for pain, function and quality of life. Compared to the exercise-only program, the combined exercise and diet program led to additional benefits — including a greater reduction in pain, greater improvements in physical function, lower use of pain medications, and significant weight loss. After both programs, participants were also less willing to undergo knee joint replacement surgery.
Lead researcher and Director of the Centre for Health, Exercise and Sports Medicine at the University of Melbourne Professor Kim Bennell, said participants lost on average 10.2 kilograms over a six-month period with four out of five participants achieving significant improvement in pain. She said 30 per cent of participants lived in regional and rural Australia.
“We are proud to have developed a program that has a strong regional and rural representation and is based on a trial which made a real difference in the lives of participants. Particularly during these times of pandemic-related travel restrictions, it is crucial Australians are able to access home-based treatments to manage their osteoarthritis symptoms, no matter where they live or what COVID restrictions are in place.”
Participant Matthew Boyd, from Toowoomba in Queensland, said his knee pain had become unbearable and was struggling to do the things he enjoyed, leading to a decline in physical activity and an increase in his weight.
“Since taking part in Better Knee, Better Me, I feel amazing. I have lost 16kg which has decreased the weight load on my knees, and my pain. I no longer take any pain relief for my knee pain, which has meant I have been able to return to all the physical activities I wasn’t able to do over the past five years. The pain in my knees no longer dictates my daily routine and I am back moving in a way I haven’t done in years,” Mr Boyd said.
Around 2.1 million Australians are currently living with osteoarthritis. The prevalence of osteoarthritis is expected to increase by 58 per cent by 2032 due to an ageing population and rising obesity rates.
Medibank Head of Member Health Service and Design Catherine Keating said Medibank wants to provide its customers with healthcare that gives them more choice and control in how they receive their care.
“It’s part of our focus on taking the lead on driving preventative health because we know our customers want personalised support to improve their health and wellbeing.”
Story Source:
Materials provided by University of Melbourne. Note: Content may be edited for style and length.

Read more →

Omicron Has Scary Mutations. They May Not Work Well Together.

The Omicron variant of the coronavirus has alarmed many scientists because of the sheer number of genetic mutations it carries — about 50 in all, including at least 26 that are unique to it. But more does not necessarily mean worse: Mutations sometimes work together to make a virus more fearsome, but they may also cancel one another out.“In principle, mutations can also work against each other,” said Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle. “However, in this case evolutionary selection is more likely to lead to the spread of a new variant with favorable than unfavorable combinations of mutations.”Still, this phenomenon, called epistasis, is why scientists are reluctant to speculate on Omicron’s attributes, even though individual mutations in the variant are associated with greater transmissibility or with an ability to dodge the body’s immune defenses.“It is important to get a sense of the full virus,” said Penny Moore, a virologist at the National Institute for Communicable Diseases in South Africa.Dr. Moore’s team is among dozens worldwide trying to understand whether current vaccines will work against Omicron. The researchers are creating artificial versions of the virus that contain all of Omicron’s mutations, rather than making judgments based on a subset of mutations.It’s a lesson researchers learned last year, when the Beta variant emerged in South Africa. They estimated that variant’s ability to evade immunity based on one particular mutation, E484K. But Beta also had two other mutations that turned out to affect sensitivity to vaccines.“The combination of those three mutations was more resistance than a virus that contained only E484K,” Dr. Moore said. Studying the single mutation “turned out to be misleading.”Omicron carries a mutation called N501Y, which is thought to allow the virus to bind to human cells more tightly. This mutation was also present in the Alpha variant and was linked to its contagiousness.“Nonetheless, it ended up being Delta, which doesn’t have that particular mutation, that was more even more transmissible than Alpha,” Dr. Bloom said. “That’s because Delta had other mutations that enhance transmissibility.”A variant’s contagiousness depends on how well the virus binds to receptors on human cells, but also on the stability of the virus, where in the airways it replicates and how much of it is exhaled.Omicron has a cluster of mutations that are all linked to tighter binding to human cells. “But acting together, they might have a somewhat different effect,” Dr. Bloom said. For that reason, he added, he cannot predict how the variant will act in the body.That will require laboratory studies, which are underway across the globe.

Read more →

Heart repair and regeneration after a heart attack

Twenty years ago, clinicians first attempted to regenerate a failing human heart by injecting muscle myoblasts into the heart during a bypass operation. Despite high initial hopes and multiple experimental and clinical studies since then, outcomes have been neutral or marginally positive for a wide variety of attempts to remuscularize an injured heart.
Yet hope remains that current and future strategies will yield clinical regenerative heart therapies, nine experts explain in a Journal of the American College of Cardiology state-of-the-art review, “Basic and translational research in cardiac repair and regeneration.”
The challenge is this: A heart attack kills heart muscle cells, leading to a scar that weakens the heart, often causing eventual heart failure. The lack of muscle repair is due to the very limited ability of mammalian heart muscle cells to proliferate, except during a brief period around birth.
In the review, the experts — coordinated by Jianyi “Jay” Zhang, M.D., Ph.D., chair of the University of Alabama at Birmingham Department of Biomedical Engineering — focus on three topics. First are several recent clinical trials with intriguing results. Second is the current trend of using cell-derived products like exosomes rather than muscle cells to treat the injured heart. For the third topic, authors discuss likely future experiments to replace a myocardial scar with heart muscle cells by “turning back the clock” of the existing cardiomyocytes, rather than trying to inject exogenous cells. Such efforts are an attempt to reverse the inability of mature mammalian heart muscle cells to proliferate.
Clinical trials
One of the interesting clinical trials reviewed involved giving cardiosphere-derived cells to patients with Duchenne muscular dystrophy, a disease that affects both heart and skeletal muscles.

Read more →

De-cluttering may not help people with dementia

A clutter-free environment may not help people with dementia carry out daily tasks — according to a new study from the University of East Anglia.
Researchers studied whether people with dementia were better able to carry out tasks, such as making a cup of tea, at home — surrounded by their usual clutter — or in a clutter-free environment.
They were surprised to find that participants with moderate dementia performed better when surrounded by their usual clutter.
But the different environments made no difference to people with mild and severe dementia, who were able to perform at the same level in both settings.
Prof Eneida Mioshi, from UEA’s School of Health Sciences, said: “The majority of people with dementia live in their own home and usually want to remain living at home for as long as possible.
“So it’s really important to know how people with dementia can be best supported at home — one possible route would be by adapting the physical environment to best suit their needs.

Read more →

Which glioblastoma patients will respond to immunotherapy?

Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit from immunotherapy.
The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.
“This is an important breakthrough for patients who have not had an effective treatment in the cancer drug arsenal available to them,” said Dr. Adam Sonabend, the senior/corresponding author of this study, and associate professor of neurosurgery at Northwestern University Feinberg School of Medicine and a Northwestern Medicine brain-tumor neurosurgeon. “It might ultimately influence the decision on how to treat glioblastoma patients and which patients should get these drugs to prolong their survival.”
“Our study emphasizes important immune cells that might be relevant for response to immunotherapy. We hope that ultimately this benefits glioblastoma patients,” said Victor Arrieta, a post-doctoral scientist at the Sonabend lab and the first author of this study.
The immunotherapy response marker now needs to be validated in a clinical trial to make sure the study findings are reproducible and applicable to any glioblastoma patient, Sonabend said. He also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
The study was published in Nature Cancer Nov. 29.

Read more →

Steam disinfection of baby bottle nipples exposes babies and the environment to micro- and nanoplastic particles

Using a new microspectroscopic technique, collaborating scientists at the University of Massachusetts Amherst and Nanjing University in China have found that steam disinfection of silicone-rubber baby bottle nipples exposes babies and the environment to micro- and nanoplastic particles.
The health and environmental risks of these very fine particles are still unknown, but microplastic pollution is a growing global concern on land, in the seas and in human bodies. The research is the first to identify this new source of microplastic contamination.
“Babies are the most sensitive group for any contaminants, not only microplastics (< 5 mm by definition)," says Baoshan Xing, professor of environmental and soil chemistry and director of the UMass Amherst Stockbridge School of Agriculture and co-corresponding author of the research, published in the journal, Nature Nanotechnology. "Conventional techniques are unable to detect these small particles, and the smaller the particles, the larger the physiological effect." Xing collaborated with lead author Yu Su and co-corresponding author Rong Ji, both environmental scientists in Nanjing University's School of the Environment, as well as other colleagues in China. "Silicone rubber was considered to be a thermally stable polymeric material in the past, but we noticed that it undergoes aging after repeated moist heat disinfections," Su says. "The aging and decomposition of plastics are a major source of microplastics in the environment. We proposed and confirmed that silicone rubber can be decomposed by moist heating to microplastics, even nanoplastics (< 1 µm)." Previous research by Xing, who has been named to an annual list of the most highly cited researchers every year since the analytics began in 2014, and colleagues in China showed that nanoplastics -- known to widely pollute oceans, surface waters and lands -- are internalized by plants and also reduce lipid digestion in a simulated human gastrointestinal system. Traditional techniques are unable to detect particles smaller than about 20 micrometers, which is roughly half the size of a human hair's thickness. At Nanjing University, researchers examined the rubber nipples using optical photothermal infrared (O-PTIR) microspectroscopy, the new and emerging technique that is able to analyze a material's composition and morphology. The microspectroscope revealed numerous flake- or oil-film-shaped micro- and nanoplastics as small as 0.6 micrometers, or 600 nanometers, in the wash waters of the steam-disinfected rubber nipples. The technique also showed submicrometer-resolved steam etching on and chemical modification of the nipple surface. "The results indicated that by the age of one year, a baby could ingest >0.66 million elastomer-derived micro-sized plastics (MPs)… Global MP emission from teat disinfection may be as high as 5.2 × 1013 particles per year,” the research paper states.
Xing and colleagues point out that similar silicone-rubbed-based consumer products, including bakeware and sealing rings in cups and cooking appliances, are also likely to produce micro- and nanoplastic particles when heated at or above 100 degrees C. They will continue their research into the release of particles into the environment from various plastic objects.
“We’ve identified this significant new source of microplastics to the environment,” Xing says. “Some plastics go into the sewer systems. They get into the water and landfills. They have such a long lifetime in the environment because they don’t decompose readily.”
Rong Ji, of Nanjing University, adds, “The behaviors of these silicon rubber-derived micro- and nanoplastics in the environment are unclear. Further research is needed to clarify their potential risks to both humans and the environment.”

Read more →

'Transformational' approach to machine learning could accelerate search for new disease treatments

Researchers have developed a new approach to machine learning that ‘learns how to learn’ and out-performs current machine learning methods for drug design, which in turn could accelerate the search for new disease treatments.
The method, called transformational machine learning (TML), was developed by a team from the UK, Sweden, India and Netherlands. It learns from multiple problems and improves performance while it learns.
TML could accelerate the identification and production of new drugs by improving the machine learning systems which are used to identify them. The results are reported in the Proceedings of the National Academy of Sciences.
Most types of machine learning (ML) use labelled examples, and these examples are almost always represented in the computer using intrinsic features, such as the colour or shape of an object. The computer then forms general rules that relate the features to the labels.
“It’s sort of like teaching a child to identify different animals: this is a rabbit, this is a donkey and so on,” said Professor Ross King from Cambridge’s Department of Chemical Engineering and Biotechnology, who led the research. “If you teach a machine learning algorithm what a rabbit looks like, it will be able to tell whether an animal is or isn’t a rabbit. This is the way that most machine learning works — it deals with problems one at a time.”
However, this is not the way that human learning works: instead of dealing with a single issue at a time, we get better at learning because we have learned things in the past.
“To develop TML, we applied this approach to machine learning, and developed a system that learns information from previous problems it has encountered in order to better learn new problems,” said King, who is also a Fellow at The Alan Turing Institute. “Where a typical ML system has to start from scratch when learning to identify a new type of animal — say a kitten — TML can use the similarity to existing animals: kittens are cute like rabbits, but don’t have long ears like rabbits and donkeys. This makes TML a much more powerful approach to machine learning.”
The researchers demonstrated the effectiveness of their idea on thousands of problems from across science and engineering. They say it shows particular promise in the area of drug discovery, where this approach speeds up the process by checking what other ML models say about a particular molecule. A typical ML approach will search for drug molecules of a particular shape, for example. TML instead uses the connection of the drugs to other drug discovery problems.
“I was surprised how well it works — better than anything else we know for drug design,” said King. “It’s better at choosing drugs than humans are — and without the best science, we won’t get the best results.”
Story Source:
Materials provided by University of Cambridge. The original text of this story is licensed under a Creative Commons License. Note: Content may be edited for style and length.

Read more →

How obesity damages the skeletal muscle metabolism

A decline in metabolism and endurance of skeletal muscle is commonly observed in obese patients, but the underlying mechanism is not well-understood. A research team led by Dr Chi Bun CHAN, Assistant Professor from School of Biological Sciences, Faculty of Science, the University of Hong Kong (HKU), uncovers a new mechanism to explain how obesity jeopardizes the functions of skeletal muscle and provides a potential treatment against the disease. The research findings have recently been published in world-leading scientific journal Autophagy.
Obesity is a metabolic disorder with increasing prevalence in modern society. Since 1970s, the global number of obese people has trebled and reached 650 million (~ 13% of the total global population) in 2016. It is widely known that obesity provokes detrimental outcomes in multiple human organs and causes numerous chronic disorders such as diabetes, hypertension, fatty liver diseases, and atherosclerosis. Fat metabolism in the skeletal muscle of obese patients is slower than that of healthy people, which scientists believe is a consequence of abnormal functions in mitochondria (the powerhouses of a cell that convert nutrients into biological energy). However, how obesity impairs the activity of mitochondria is a long unresolved question.
To study the functional impacts of obesity on the skeletal muscle, Dr Chan’s team developed a special obesified mouse model by removing the gene of brain-derived neurotrophic factor (BDNF) exclusively in their skeletal muscle. BDNF is originally identified as an important growth factor for maintaining the survival and activities of neurons. Recent studies have proposed that BDNF is also a muscle-secreted protein (i.e., myokine), but its physiological significance is unknown.
For the first time, Dr Chan’s team found that obesity reduced the amount of BDNF in the skeletal muscle of mice. They also observed that the mice without BDNF in their muscle, called ‘MBKO’ (Muscle-specific BDNF Knockout), gained more body weight and developed severer insulin resistance when the animals were fed with a high-fat diet. In addition, the research team found that MBKO mice have less energy expenditure than their control cohort.
Using a number of biochemical, histological, metabolomic, and molecular analyses, the research team further demonstrated that the mitochondria in the muscle of MBKO mice were unable to recycle, leading to the accumulation of damaged mitochondria in the tissues. Consequently, the lipid metabolism in the muscle of MBKO mice was retarded, causing more lipid accumulation to interfere with insulin sensitivity.
“Clearly, muscle-derived BDNF is a weight-control protein by increasing the energy expenditure and maintaining insulin sensitivity,” said Dr Chan.
“BDNF has long been considered a brain-localized peptide, and its importance in peripheral tissues has been underestimated. Our study provides a new insight to this area, and hopefully we can unlock more functions of this myokine using our MBKO mice,” Dr Chan further added.
In addition to the animal studies, Dr Chan’s team also utilized cultured cell models to pinpoint the molecular mechanism for the defective mitochondrial turnover in BDNF-deficient muscle cells. They found that muscle-secreted BDNF used AMPK-activated protein kinase, the well-known energy sensor in cells, to trigger the Parkin/PINK1 pathway for inducing mitophagy (a highly regulated mechanism to recycle the materials in cells in response to various challenges) in skeletal muscle.
To extend these findings to therapeutic application, the research team further tested if restoring the BDNF signaling in muscle would rescue the obesity-induced mitochondrial damage. They fed the obese mice with 7,8-dihydroxyflavone, a natural bioavailable BDNF mimetic in plants (found in the leaves of Godmania aesculifolia, a plant species in South America) currently used in the clinical trials of Alzheimer’s disease, and found that obesity-induced mitochondrial dysfunction was alleviated.
Together with their previous findings that 7,8-DHF is an effective agent in reducing body weight and improving the insulin sensitivity in obese mice (Chem Biol 2015 22: 355-369; Metabolism 2018 87: 113-122), Dr Chan’s work provides a new explanation on the pernicious nature of obesity and suggests that BDNF-signaling enhancer such as 7,8-DHF is a potential drug for obesity treatment in human beings.
This work was supported by the Hong Kong Research Grant Council, the Health and Medical Research Fund, and HKU Seed Fund for Basic Research.

Read more →